Re: Dudith Pierre-Victor, Howard L. Parnes, Gerald L. Andriole, et al. Prostate Cancer Incidence and Mortality Following a Negative Biopsy in a Population Undergoing PSA Screening. Urology 2021 Jun 26;S0090-4295(21)00539-2.

Urology ◽  
2021 ◽  
Author(s):  
Patrick Lewicki ◽  
Camilo Arenas-Gallo ◽  
Spyridon P. Basourakos ◽  
Bashir Al Hussein Al Awamlh ◽  
Siv Venkat ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Incidence ◽  
Prostate Cancer Incidence ◽  
Negative Biopsy ◽  
Psa Screening ◽  
Incidence And Mortality

scholarly journals Age specific trends in prostate cancer tests, incidence and mortality in Australia since the introduction of the Prostate Specific Antigen (PSA) test

2020 ◽  
Author(s):  
Thanya Pathirana ◽  
Rehan Sequeira ◽  
Chris Del Mar ◽  
James A Dickinson ◽  
Katy J L Bell ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Incidence ◽  
Specific Antigen ◽  
Age Groups ◽  
Prostate Cancer Incidence ◽  
Psa Screening ◽  
Prostate Biopsies ◽  
Psa Testing ◽  
Incidence And Mortality ◽  
Incidental Cancer

Abstract BackgroundPopulation trends in PSA screening and prostate cancer incidence do not perfectly correspond. We aimed to better understand relationships between trends in PSA screening, prostate cancer incidence and mortality in Australia.MethodsDescription of age standardised time trends in PSA tests, prostate biopsies, cancer incidence and mortality within Australia for the age groups: 45-74, 75-84, and 85+ years.ResultsPSA testing increased from its introduction in 1989 to a peak in 2008. It then declined in men aged 45-84 years. Prostate biopsies and cancer incidence declined from 1995 to 2000, in parallel with decrease in trans-urethral resections of prostate (TURP). After 2000, changes in biopsies and cancer incidence paralleled PSA screening in men 45-84 years, while in men ≥85 years, biopsies stabilised and incidence declined. More recently a reduction in TURP correlated with increased Dutasteride and Tamsulosin usage. Prostate cancer mortality in men aged 45-74 years remained low throughout. Mortality in men 75-84 years gradually increased until the mid 1990s, then gradually decreased. Mortality in men ≥85 years increased until the mid 1990s, then stabilised.ConclusionsAge specific prostate cancer incidence largely mirrors PSA screening rates. Most deviation may be explained by changes in management of benign prostatic disease and incidental cancer detection. The timing of the small mortality reduction in men 75-84 years is more consistent with benefits from advances in treatment than with early detection through PSA. The large increases in prostate cancer incidence with minimal changes in mortality suggest overdiagnosis.

Decade-long Trends in Prostate Cancer Incidence and Mortality in Poland, 1999–2012

2018 ◽  
Author(s):  
Urszula Wojciechowska ◽  
◽  
Lauren M. Hurwitz ◽  
Grzegorz Helicki ◽  
Jennifer Cullen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Incidence ◽  
Prostate Cancer Incidence ◽  
Incidence And Mortality

Trends in Prostate Specific Antigen (PSA) testing and prostate cancer incidence and mortality in Australia: A critical analysis

2022 ◽  
Vol 77 ◽  
pp. 102093
Author(s):  
Thanya Pathirana ◽  
Rehan Sequeira ◽  
Chris Del Mar ◽  
James A. Dickinson ◽  
Bruce K. Armstrong ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Cancer Incidence ◽  
Critical Analysis ◽  
Specific Antigen ◽  
Prostate Cancer Incidence ◽  
Psa Testing ◽  
Incidence And Mortality

scholarly journals Prostate Cancer Incidence and Mortality in Barbados, West Indies

2011 ◽  
Vol 2011 ◽  
pp. 1-10 ◽  
Author(s):  
Anselm J. M. Hennis ◽  
Ian R. Hambleton ◽  
Suh-Yuh Wu ◽  
Desiree H.-A. Skeete ◽  
Barbara Nemesure ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
African American ◽  
Cancer Incidence ◽  
West Indies ◽  
African American Men ◽  
Mortality Rates ◽  
Prostate Cancer Incidence ◽  
White American ◽  
Incidence And Mortality ◽  
The Us

We describe prostate cancer incidence and mortality in Barbados, West Indies. We ascertained all histologically confirmed cases of prostate cancer during the period July 2002 to December 2008 and reviewed each death registration citing prostate cancer over a 14-year period commencing January 1995. There were 1101 new cases for an incidence rate of 160.4 (95% Confidence Interval: 151.0–170.2) per 100,000 standardized to the US population. Comparable rates in African-American and White American men were 248.2 (95% CI: 246.0–250.5) and 158.0 (95% CI: 157.5–158.6) per 100,000, respectively. Prostate cancer mortality rates in Barbados ranged from 63.2 to 101.6 per 100,000, compared to 51.1 to 78.8 per 100,000 among African Americans. Prostate cancer risks are lower in Caribbean-origin populations than previously believed, while mortality rates appeared to be higher than reported in African-American men. Studies in Caribbean populations may assist understanding of disparities among African-origin populations with shared heredity.

Trends in Prostate Cancer Incidence and Mortality

2008 ◽  
pp. 246-257
Author(s):  
Steven Oliver ◽  
Rhidian Hurle ◽  
Owen Hughes
Keyword(s):  
Prostate Cancer ◽  
Cancer Incidence ◽  
Prostate Cancer Incidence ◽  
Incidence And Mortality
Sign in / Sign up

Export Citation Format

Share Document